p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors
about
Dinosaurs and ancient civilizations: reflections on the treatment of cancerCurrent and future trials of targeted therapies in cutaneous melanomaNeoplasia: the second decade.Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.A conserved isoleucine maintains the inactive state of Bruton's tyrosine kinaseTumour suppressor genes in chemotherapeutic drug response.p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal CancerThe relationship between promoter methylation of p16 gene and bladder cancer risk: a meta-analysis.Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt.Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutationsThe War on Cancer rages on.Are RAS mutations predictive markers of resistance to standard chemotherapy?Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.KRAS and BRAF: drug targets and predictive biomarkers.Future directions in treatment of brain metastases.Prognostic and predictive biomarkers in melanoma: an update.A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
P2860
Q24628746-31401B4A-190D-41AE-84C3-F14C7C99E5E7Q27022355-4CE92249-8C5F-480F-9078-15EAE163E8AEQ30484000-2241D7DC-8EA8-41E5-9A9C-D9A8E3993B0EQ33918101-86919D74-6BB8-4538-9B09-E34A4873A653Q34302080-C603EB71-C09F-4010-8114-140B6B500666Q36083098-7C9C76E9-85C8-4C3C-9726-7E02928E15D7Q36482470-AB7CFF2C-8615-449E-8FBA-04DFC273BD1DQ36492827-A36501F6-D455-47F1-9A66-90186558691AQ37165847-A9FAC10D-A6CC-44A5-A0A6-C962B47367D5Q37269341-9E034228-35A4-4CF3-BBBD-B3EA92D4DA71Q37478602-B970CBDD-133F-4A7B-BF1E-FAF37BC9BEB4Q37549918-3B50C394-C49F-41E3-811A-DF5633F6F66BQ37585155-4454B785-A6B5-439D-9122-BA15D5705DC6Q37745182-91AC98B2-FBBD-4B2B-BFCF-546B2ED6C017Q37815135-38D40918-7D64-495F-A417-E9790E6B56ECQ38110294-2784CFE6-C746-4C40-8FE1-6D72469F2EFCQ38653619-9B8B74A4-047A-45BB-AD08-158985933AA5Q39793029-CC54BECE-F0C3-40D1-BE31-E218D13BFF77Q55068437-3F9C5D2D-A40C-4A41-A71A-D3056C163C80
P2860
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
p16INK4a expression and absenc ...... sensitivity in melanoma tumors
@en
type
label
p16INK4a expression and absenc ...... sensitivity in melanoma tumors
@en
prefLabel
p16INK4a expression and absenc ...... sensitivity in melanoma tumors
@en
P2093
P2860
P50
P356
P1433
P1476
p16INK4a expression and absenc ...... sensitivity in melanoma tumors
@en
P2093
James Indsto
John F Thompson
Lyndee L Scurr
Margaret Lett
Ruth Dunleavey
P2860
P304
P356
10.1593/NEO.08702
P577
2008-11-01T00:00:00Z